- Oops!Something went wrong.Please try again later.
HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer's disease.
The data support the therapeutic cognitive potential of HT-ALZ after chronic oral dosing.
All behavioral tests performed after >5 weeks of treatment showed a significant improvement in the HT-ALZ treated groups compared to the vehicle-treated groups, with similar cognitive and behavioral trends in the HT-ALZ-treated groups compared to the wild-type (non-AD) animals.
Other behavioral assessments performed at earlier treatment periods (less than five weeks) with HT-ALZ did not significantly improve compared to vehicle-treated animals.
However, they were trending positively toward improvement, suggesting a time-dependent improvement after initiation of HT-ALZ treatment.
These other behavioral assessments are repeated after longer HT-ALZ dosing periods (eg, six weeks).
Price Action: HOTH shares are up 28.9% at $0.52 during the market session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.